Globalisation and other recent developments such as stricter quality control criteria, evolving technologies, and the increasing stringency of regulatory standards, have imposed enormous pressures on biotechnology drug manufacturers. With such difficult basic conditions, only a limited few compounds will ever make it to Phase III, and even fewer will make it through to approval and to commercial manufacturing. Paul Nelles, at Vetter Pharma-Fertigung GmbH & Co. KG, explores whether a contract development and manufacturing organisation (CDMO) can help lower this bar? Or perhaps help to lift you higher, thus helping to improve a company’s odds of achieving success?

https://international-pharma.com/wp-content/uploads/2013/06/1-Grabbing-Hold-of-the-Bar-of-Success-in-Drug-Development.pdf